Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Differential expression of drug metabolizing enzymes in primary and secondary liver neoplasm: immunohistochemical characterization of cytochrome P4503A and glutathione-S-transferase

Abstract

The question whether expression of drug metabolizing enzymes in human liver is altered by liver neoplasm remains controversial; however, the ability or unability of tumour cells to metabolize certain drugs may be important for developing therapeutic strategies. We therefore investigated the abundance and localization of two classes of drug metabolizing enzymes [cytochrome P4503A (CYP3A) and pi-type glutathione-S-transferase] by means of immunohistochemistry (standard ABC technique) in patients with hepatocellular carcinoma (HCC, n=16) and with liver metastasis from adenocarcinoma (n=53) in comparison to normal controls (n=5). The distribution of CYP3A in normal liver samples showed a characteristic pattern of four to five layers of stained hepatocytes surrounding the central vein. Eleven out of 16 cases of HCC showed expression of CYP3A; staining was less intense than in normal liver and zonation was completely lost. In contrast, only 5 out of 53 samples of metastasis stained positively for CYP3A. The difference between primary and secondary neoplasm was statistically significant (chi-square, P<0.0001). Pi-type glutathione-S-transferase (GST) stained positively in 9 out of 16 HCC and in 48 out of 53 cases of liver metastasis (chi-square, P<0.01) indicating a higher percentage of immunostaining in liver metastasis. In summary, we observed differenes in the abundance and distribution pattern of CYP3A and GST between primary and secondary neoplasma of human liver and in comparison to normal controls. In combination with established methods these data may contribute to the establishment of reliable test systems for distinguishing primary from secondary liver tumours. The mechanisms of different expression of drug metabolizing enzymes in relation to tumour type and the possible consequences for drug action remain to be elucidated.

This is a preview of subscription content, log in to check access.

References

  1. Baron J (1991) In situ sites for xenobiotic activation and detoxication: implications for the differential susceptibility of cells to the toxic actions of environmental chemicals. Prog Histochem Cytochem 23:32–44

  2. Baron J, Redick JA, Guengerich FP (1981) An immunohistochemical study on the localizations and distributions of phenobarbital- and 3-methylcholanthrene-inducible cytochromes P-450 within the livers of untreated rats. J Biol Chem 256:5931–5937

  3. Baron J, Redick JA, Guengerich FP (1982) Effects of 3-methylcholanthrene, β-naphthoflavone, and phenobarbital on the 3-methylcholanthrene-inducible isoenzyme of cytochrome P-450 within centrilobar, midzonal and periportal hepatocytes. J Biol Chem 257:953–957

  4. Beaune P, Kremers F, Letawe-Goujon F, Gielen JE (1985) Monoclonal antibodies against human liver cytochrome P-450. Biochem Pharmacol 34:3547–3552

  5. Becker FF, Stout DLA (1986) A constitutive deficiency in monooxygenase system of spontaneous mouse liver tumors. Cancer Res 46:2693–2696

  6. Bohrer MH, Hastka J, Verbecke CS (1992) Differentialdiagnose von hepatischen Tumormanifestationen in der bioptischen Diagnostik. Immunhistochemische Abgrenzung von Leberzellkarzinomen. Tumordiagn Ther 13:187–189

  7. Botsch S, Gautier JC, Beaune P, Eichelbaum M, Kroemer HK (1993) Identification and characterization of the cytochrome P450 enzymes involved in N-dealkylation of propafenone: Molecular base for interaction potential and variable disposition of active metabolites. Mol Pharmacol 43:120–126

  8. Brumm C, Schulze C, Charels K, Morohoshi T, Kloppel G (1989) The significance of alpha-fetoprotein and other tumor markers in differential immunocytochemistry of primary liver tumors. Histopathology 14:503–513

  9. Cairns J, Wright C, Cattan AR, Hall AG, Cantwell BJ, Harris AL, Horne CHW (1992) Immunohistochemical demonstration of glutathione-S-transferases in primary breast carcinomas. J Pathol 166:19–25

  10. Clarke L, Waxman DJ (1989) Oxidative metabolism of cyclophosphamide: identification of the hepatic monoxygenase catalysts of drug activation. Cancer Res 49:2344–2350

  11. Cohen MB, Haber MM, Holly EA, Ahn DK, Bottles K, Stoloff A (1991) Cytologic criteria to distinguish hepatocellular carcinoma from nonneoplastic liver. Am J Clin Pathol 95:125–130

  12. Doehmer J, Seidel A, Oesch F, Glatt HR (1990) Genetically engineered V79 Chinese hamster cells metabolically activate the cytostatic drug cyclophosphamide and ifosfamide. Environ Health Persp 88:63–65

  13. Eriksson LC, Torndal UB, Andersson GB (1983) Isolation and characterization of endoplasmatic reticulum and Golgi apparatus from hepatocyte nodules in male Wistar rats. Cancer Res 3335–3347

  14. Faulder CG, Hirrell PA, Hume R, Strange RC (1987) Studies of the development of basic, neutral and acidic isoenzymes of glutathione S-transferase in human liver, adrenal, kidney and spleen. Biochem J 241:221–228

  15. Fritz P, Mueller J, Wegner G, Braun U, Grau A, Tuczek HV, Moessner E, Schenk R (1985) Immunohistochemie: Theoretische Möglichkeiten, praktische Anwendungen. Zentralbl Allg Pathol Pathol Anat 130:187–193

  16. Gonzalez FJ (1990) Molecular genetics of the P450 superfamily. Pharmacol Ther 45:1–38

  17. Gonzalez FJ (1992) Human cytochromes P450: problems and prospects. Trends Pharmacol Sci 13:346–352

  18. Guengerich FP (1991) Mechanisms of catalysis and substrate specificity of human cytochrome P450 enzymes. In: Bock KW, Gerock W, Matern S, Schmid R (eds) Hepatic metabolism and disposition of endo- and xenobiotics. Kluwer, Dordrecht Boston Utrecht, pp 85–96

  19. Guengerich FP, Martin MV, Beaune P, Kremers P, Wolff T, Waxman DJ (1986) Characterization of rat and human liver microsomal cytochrome P450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J Biol Chem 261:5051–5060

  20. Hayes PC, Harrison DJ, Bouchier IAD, McLellan LI, Hayes JD (1989) Cytosolic and microsomal glutathione-S-transferase isoenzymes in normal human liver and intestinal epithelium. Gut 30:854–859

  21. Hirata S, Odajima T, Kohama, Gen-iku, Ishigaki S, Niitsu Y (1992) Significance of glutathione-S-transferase-pi as a tumor marker in patients with oral cancer. Cancer 70:2381–2387

  22. Houn HY, Sanders MM, Walker EM, Pappas AA (1991) Fine needle aspiration in the diagnosis of liver neoplasms: a review. Ann Clin Lab Sci 21:2–11

  23. Howie WF, Forrester LM, Glancey MJ, Schlager M, Powis G, Beckett GJ, Hayes JD, Wolf CR (1990) Glutathione-S-transferase and glutathione peroxidase expression in normal and tumor human tissues. Carcinogenesis 11:451–458

  24. Hsu SM, Raine L, Fanger H (1981) The use of anti-avidin antibody and avidin-biotin-complex in immunoperoxidase technics. Am J Clin Pathol 75:816–821

  25. Hurlimann J, Gardiol D (1991) Immunohistochemistry in the differential diagnosis of liver carcinomas. Am J Surg Pathol 15:280–288

  26. Jacolot F, Simon I, Dreano Y, Beaune P, Riche C, Berthou F (1991) Identification of the cytochrome P450IIIA family as the enzymes in the N-demethylation of tamoxifen in human liver microsomes. Biochem Pharmacol 12:1911–1919

  27. Johnson DE, Powers CN, Rupp G, Frable WJ (1992) Immunocytochemical staining of fine needle aspiration biopsies of the liver as a diagnostic tool for hepatocellular carcinoma. Mol Pathol 5:117–123

  28. Kodate C, Fukushi A, Narita T, Kudo H, Soma Y, Sato K (1986) Human placental form of glutathione-S-transferase (GST-Pi) as a new immunohistochemical marker for human colonic carcinoma. Jpn J Cancer Res 77:226–229

  29. Mannervik B, Alin P, Guthenberg C, Jennson H, Tahir MK, Warholm M, Jornvall H (1985) Identification of three classes of cytosolic glutathione-S-transferase common to several mammalian species: correlation between structural data and enzymatic properties. Proc Natl Acad Sci USA 82:7202–7206

  30. Mclean AJ, Morgan DJ (1991) Clinical pharmacokinetics in patients with liver disease. Clin Pharmacokinet 21:42–69

  31. Mouelhi EM, Didolkar MS, Elias EG, Guengerich FP, Kauffman FC (1987) Hepatic drug-metabolizing enzymes in primary and secondary tumors of human liver. Cancer Res 47:460–466

  32. Murray GI, Barnes TS, Sewell HF, Ewen SWB, Melvin WT, Burke D (1988) The immunocytochemical localisation and distribution of cytochrome P450 in normal human hepatic and extrahepatic tissues with a monoclonal antibody to human cytochrome P450. Br J Clin Pharmacol 25:465–475

  33. Murray GI, Paterson PJ, Weaver RJ, Ewen SWB, Melvin WT, Burke MD (1993) The expression of cytochrome P450, epoxide hydrolase and glutathione-S-transferase in hepatocellular carcinoma. Cancer 71:36–43

  34. Nebert DW, Nelson DR, Feyereisen R, Fuji-Kuriyama Y, Coon MJ, Estabrook RW, Gonzalez FJ, Guengerich FP, Gunsalus IC, Johnson EF, Loper JC, Sato R, Waterman MR, Waxman DJ (1991) The P450 superfamily: update on new sequences, gene mapping and recommended nomenclature. DNA Cell Biol 10:1–14

  35. Sachs L (1983) Angewandte Statistik. Springer, Berlin Heidelberg New York

  36. Satoh K, Kitahara A, Soma J, Inaba Y, Hatayama I, Sato K (1985) Purification, induction, and distribution of placental glutathione transferase: a new marker enzyme for preneoplastic cells in the rat chemical hepatocarcinogenesis. Proc Natl Acad Sci USA 82:3964–3968

  37. Sherman M, Campbell JA, Titmuss SA, Kew MC, Kirsch RE (1983) Glutathione-S-transferase in human hepatocellular carcinoma. Hepatology 3:170–176

  38. Stockman PK, Beckett GJ, Hayes D (1985) Identification of a basic hybrid glutathione-S-transferase from human liver. Biochem J 227:457–465

  39. Stout DL, Becker FF (1986) Heme enzyme patterns in genetically and chemically induced mouse liver tumors. Cancer Res 46:2756–2759

  40. Terasaki S, Terada T, Nakanuma Y, Nonomura A, Unoura M, Kobayashi K (1991) Argyrophilic nucleolar organizer regions and alpha-fetoprotein in adenomatous hyperplasia in human cirrhotic livers. Am J Clin Pathol 95:850–857

  41. Vos RME, van Bladeren PJ (1990) Glutathione-S-transferase in relation to their role in the biotransformation of xenobiotics. Chem Biol Interact 75:241–265

  42. Watkins PB, Wrighton SA, Maurel P, Schuetz EG, Mendez-Picon G, Parker GA, Guzelian PS (1985) Identification of an inducible form of cytochrome P450 in human liver. Proc Natl Acad Sci USA 82:6310–6314

  43. Wolf CR, Moll E, Friedberg T, Oesch F, Buchmann A, Kuhlmann WD, Kunz HW (1984) Characterization, localization and regulation of a novel phenobarbital-inducible form of cytochrome P450-reductase, glutathione transferases and microsomal epoxide hydrolase. Carcinogenesis 5:993–1000

  44. World Health Organization (1978) International histological classification of tumours (no. 20) Histological typing of tumours of the liver, biliary tract and pancreas

  45. Wrighton SA, Stevens JC (1992) The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol 22:1–21

Download references

Author information

Correspondence to P. Fritz.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Fritz, P., Behrle, E., Beaune, P. et al. Differential expression of drug metabolizing enzymes in primary and secondary liver neoplasm: immunohistochemical characterization of cytochrome P4503A and glutathione-S-transferase. Histochemistry 99, 443–451 (1993). https://doi.org/10.1007/BF00274096

Download citation

Keywords

  • Hepatocellular Carcinoma
  • Normal Control
  • Liver Metastasis
  • Human Liver
  • Normal Liver